Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast RYBREVANT Coverage Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    RYBREVANT and RYBREVANT FASPRO Coverage for EGFR-Mutated Non-Small Cell Lung Cancer

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and Part B coverage criteria for physician-administered intravenous RYBREVANT and subcutaneous RYBREVANT FASPRO in adults with recurrent, advanced, or metastatic NSCLC and qualifying EGFR mutations.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyRYBREVANT and RYBREVANT FASPRO Coverage for EGFR-Mutated Non-Small Cell Lung Cancer
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 14, 2026
    Last ReviewMay 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for physician-administered IV RYBREVANT or subcutaneous RYBREVANT FASPRO.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered NSCLC indication pathways
    18+Minimum member age
    12 moMaximum approval period
    2Covered administration routes
    5Monitoring risk categories
    350 mg/7 mLRYBREVANT vial presentation

    Coverage Criteria

    Initial Approval Criteria

    Covered when all general requirements, at least one qualifying disease-treatment pathway, and dose/regimen requirements are met.

    General approval requirements: The request is for physician-administered IV RYBREVANT or subcutaneous RYBREVANT FASPRO in an office or hospital outpatient department; the product cannot be self-administered; the member has recurrent, advanced, or metastatic NSCLC; the prescriber is an oncologist or has consulted with an oncologist; and the member is at least 18 years old.Age ≥ 18 years

    Qualifying disease-treatment pathway

    • EGFR exon 20 insertion pathway: Disease is positive for an EGFR exon 20 insertion mutation and RYBREVANT or RYBREVANT FASPRO is prescribed either as first-line therapy in combination with carboplatin and pemetrexed or as a single agent for disease that has progressed on or after platinum-based therapy.EGFR exon 20 insertion mutation
    • Post-EGFR tyrosine kinase inhibitor pathway: RYBREVANT or RYBREVANT FASPRO is prescribed as subsequent therapy after progression on an EGFR tyrosine kinase inhibitor; disease is positive for an EGFR exon 19 deletion or exon 21 L858R substitution mutation; and treatment is combined with carboplatin and pemetrexed.Progression after EGFR tyrosine kinase inhibitor

      Examples of prior EGFR tyrosine kinase inhibitors include erlotinib, Gilotrif, Lazcluze, and Tagrisso.

    • Lazcluze combination pathway: RYBREVANT or RYBREVANT FASPRO is combined with Lazcluze for EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive disease and is used as first-line therapy, continued after progression on the RYBREVANT/Lazcluze combination for asymptomatic disease, symptomatic brain lesions, or symptomatic systemic limited progression, or used after progression following specified Tagrisso-based therapy.EGFR exon 19 deletion or exon 21 L858R substitution mutation

      Specified prior therapy includes Tagrisso for symptomatic systemic disease with multiple lesions or Tagrisso with carboplatin or cisplatin and pemetrexed.

    • Brain metastases pathway: The member has brain metastases; disease is positive for an EGFR exon 19 deletion or exon 21 L858R substitution mutation; and RYBREVANT or RYBREVANT FASPRO is combined with carboplatin and pemetrexed or Lazcluze.Brain metastases plus qualifying EGFR mutation
    Dose and regimen requirements: The requested dose does not exceed the maximum recommended dose, or an off-label dose is supported by practice guidelines or peer-reviewed literature. The prescribed regimen must be FDA-approved or recommended by NCCN, and dosing must follow FDA-approved labeling or accepted standards of medical practice.Maximum recommended dose unless supported off-label

    The policy also requires compliance with LCD L37205, Chemotherapy Drugs and their Adjuncts.

    Continuation and Reauthorization

    Continuation or reauthorization is available when the applicable disease pathway remains satisfied, treatment remains clinically appropriate, and dosing continues to meet policy requirements.

    Continuation pathways: Continuation may be authorized following disease progression on the RYBREVANT and Lazcluze combination for asymptomatic disease, symptomatic brain lesions, or symptomatic systemic limited progression, or as subsequent therapy after specified Tagrisso-based treatment for qualifying disease.Continuation after specified progression

    Continuation must remain within the Lazcluze or brain-metastases pathways described in the approval criteria.

    Reauthorization duration and dose: Initial or reauthorization approval may be granted for up to 12 months, and the dose must follow FDA-approved labeling or accepted standards of medical practice.Up to 12 months

    The regimen must also be FDA-approved, recommended by NCCN, or supported by accepted medical practice as applicable, and must follow LCD L37205, Chemotherapy Drugs and their Adjuncts.

    Self-administration is excluded. RYBREVANT FASPRO must be administered subcutaneously by a health care professional in an office or hospital outpatient department. It cannot be dispensed or intended for administration by the member at home.

    Do not substitute RYBREVANT FASPRO for or with intravenous RYBREVANT products. The subcutaneous product has different recommended dosage and administration requirements than intravenous RYBREVANT.

    Coding and Product Details

    HCPCS CodesHCPCS
    J9061Injection, amivantamab-vmjw, 2 mg
    J9999Not otherwise classified, antineoplastic drugs
    C9399Unclassified drugs or biologicals
    11-digit NDCNDC
    57894-0501-01RYBREVANT FASPRO 1600 mg/20,000 units, 11-digit NDC
    57894-0510-01RYBREVANT FASPRO 1600 mg/20,000 units, 11-digit NDC
    57894-0514-01RYBREVANT FASPRO 2240 mg/28,000 units, 11-digit NDC
    57894-0515-01RYBREVANT FASPRO 2400 mg/30,000 units, 11-digit NDC
    57894-0522-01RYBREVANT FASPRO 3520 mg/44,000 units, 11-digit NDC
    10-digit NDCNDC
    57894-501-01RYBREVANT FASPRO 1600 mg/20,000 units, 10-digit NDC
    57894-510-01RYBREVANT FASPRO 1600 mg/20,000 units, 10-digit NDC
    57894-514-01RYBREVANT FASPRO 2240 mg/28,000 units, 10-digit NDC
    57894-515-01RYBREVANT FASPRO 2400 mg/30,000 units, 10-digit NDC
    57894-522-01RYBREVANT FASPRO 3520 mg/44,000 units, 10-digit NDC
    Minimum Age
    Minimum ageAt least 18 years
    Member populationAdult members with recurrent, advanced, or metastatic non-small cell lung cancer
    Coverage requirementThe member must be at least 18 years old for approval
    Weight-Based Dosing Threshold
    Weight categoriesBaseline actual body weight under 80 kg or at least 80 kg
    Dose determinationDosing differs according to the member’s baseline actual body weight

    Provider Submission and Administration Requirements

    Prior Authorization

    Prior Authorization and Duration

    Prior authorization is required for RYBREVANT or RYBREVANT FASPRO. Initial authorization and reauthorization may be approved for up to 12 months.

    • Submit the requested regimen, clinical documentation, and supporting records with the authorization request.
    • Coverage follows FDA-approved labeling or accepted standards of medical practice and must follow LCD L37205, Chemotherapy Drugs and their Adjuncts.
    Documentation Required

    EGFR Mutation Testing Required

    Document the qualifying EGFR mutation using an FDA-approved test before requesting coverage. Testing may use tumor or plasma specimens and may be performed at any time from initial diagnosis; repeat testing is not required once EGFR mutation status has been established.

    • For exon 20 insertion disease, document a positive EGFR exon 20 insertion mutation.

    Medication Background

    RYBREVANT (amivantamab-vmjw) is a bispecific antibody directed against the epidermal growth factor receptor (EGFR) and MET receptor. RYBREVANT FASPRO combines amivantamab with hyaluronidase for subcutaneous administration. The policy addresses these products for adults with recurrent, advanced, or metastatic non-small cell lung cancer involving specified activating EGFR mutations and treatment histories.

    Clinical Definitions

    EGFR Exon 20 Insertion Mutation
    MutationEGFR exon 20 insertion mutation
    DefinitionA mutation involving insertion changes in exon 20 of the epidermal growth factor receptor gene
    Covered testing contextThe mutation is identified in NSCLC using an FDA-approved test
    EGFR Exon 19 or Exon 21 Mutation
    Qualifying mutationsEGFR exon 19 deletion or exon 21 L858R substitution mutation
    Testing requirementThe mutation must be identified using an FDA-approved test
    Specimen options

    Initial Therapy

    Initial Therapy Criteria

    Initial therapy is covered when all general eligibility requirements and at least one qualifying EGFR mutation and treatment pathway are met.

    General eligibility: The member has recurrent, advanced, or metastatic NSCLC, is at least 18 years old, and treatment is prescribed by or in consultation with an oncologist.Age ≥ 18 years

    Qualifying initial treatment indication

    • EGFR exon 20 insertion mutation: Disease is positive for an EGFR exon 20 insertion mutation and RYBREVANT or RYBREVANT FASPRO is prescribed as first-line therapy in combination with carboplatin and pemetrexed or as a single agent after progression on or after platinum-based therapy.EGFR exon 20 insertion mutation

    Continuation and Reauthorization

    Continuation Therapy

    Continue treatment until disease progression or unacceptable toxicity. Reauthorization may be granted for up to 12 months when the applicable criteria remain satisfied.

    Continuation treatment: Treatment continues until disease progression or unacceptable toxicity. Continuation pathways are allowed after specified progression on the RYBREVANT/Lazcluze combination or after specified Tagrisso-based treatment, and the applicable disease, EGFR mutation, treatment combination, and oncology eligibility criteria remain satisfied.Continue until disease progression or unacceptable toxicity
    Reauthorization duration and regimen: Reauthorization may be granted for up to 12 months when criteria remain satisfied. The regimen must be FDA-approved, recommended by NCCN, or supported by accepted standards of medical practice as applicable, and dosing must follow FDA-approved labeling or accepted standards of medical practice.Up to 12 months per authorization

    Administration Site Requirements

    Billing Rule

    Administer IV RYBREVANT in the office

    Administer IV RYBREVANT as a physician-administered infusion in an office setting. The product cannot be self-administered.

    • Use a qualified physician or other health care professional for administration.
    • Document the office-based administration setting.
    Billing Rule

    Administer IV RYBREVANT in hospital outpatient

    Administer IV RYBREVANT as a physician-administered infusion in a hospital outpatient department. The product cannot be self-administered.

    • Use a qualified physician or other health care professional for administration.
    • Document the hospital outpatient administration setting.
    Policy Summary
    PayerGold Coast Health Plan
    PolicyRYBREVANT and RYBREVANT FASPRO Coverage for EGFR-Mutated Non-Small Cell Lung Cancer
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 14, 2026
    Last ReviewMay 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for physician-administered IV RYBREVANT or subcutaneous RYBREVANT FASPRO.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Product DetailsProvider Submission and Administration RequirementsMedication BackgroundClinical DefinitionsInitial TherapyContinuation and ReauthorizationAdministration Site Requirements
    Later weight changesSubsequent body weight changes do not require dose adjustment
  1. For exon 19 deletion or exon 21 L858R substitution indications, document the applicable positive EGFR result.
  2. Identify the FDA-approved testing method and include the test result in the submission.
  3. Documentation Required

    Clinical Eligibility Records

    Submit records establishing the member’s clinical eligibility and the requested treatment context. Documentation must support the disease status, treatment line, regimen, and applicable clinical circumstances.

    • Recurrent, advanced, or metastatic NSCLC diagnosis.
    • Member is age 18 years or older.
    • Prescriber is an oncologist or is working in consultation with an oncologist.
    • Document prior therapies, progression, combination partners, and brain metastases when applicable.

    Unsupported block type: documentation

    Documentation Required

    Pregnancy and Contraception Counseling

    Before initiating RYBREVANT or RYBREVANT FASPRO, verify pregnancy status for females of reproductive potential and document counseling about embryo-fetal risk. Counsel these patients to use effective contraception during treatment and for three months after the last dose.

    • Document pregnancy-status verification when applicable before treatment initiation.
    • Advise pregnant patients and females of reproductive potential of the potential risk to the fetus.
    • Document effective-contraception counseling for treatment and the three months after the final dose.
    Denial Risk

    Administration Setting Required

    RYBREVANT must be administered by a qualified professional as an IV infusion, and RYBREVANT FASPRO must be administered as a subcutaneous injection in an office or hospital outpatient department. The drugs cannot be self-administered.

    • Administration setting: physician office or HOPD.
    • Coverage may be denied when administration is self-administered or otherwise occurs outside the required qualified-professional setting.
    Denial Risk

    Disease and Prescriber Criteria

    Requests may be denied when the member does not meet the NSCLC, age, oncology-prescriber, mutation, prior-treatment, or regimen requirements. Submit documentation showing that all applicable criteria are satisfied.

    • Diagnosis must be recurrent, advanced, or metastatic NSCLC.
    • Member must be at least 18 years old.
    • Treatment must be prescribed by or in consultation with an oncologist.
    • Document the applicable EGFR mutation and required treatment line, progression history, combination therapy, and brain-metastasis criteria.
    Denial Risk

    RYBREVANT FASPRO Hypersensitivity

    RYBREVANT FASPRO is contraindicated in patients with known hypersensitivity to hyaluronidase or any of its excipients.

    • Screen for and document relevant hypersensitivity before administration.
    Denial Risk

    Dose Exceeds Supported Limit

    Requested dosing may be denied when it exceeds the maximum recommended dose unless the prescriber provides supporting evidence for the dose.

    • Dose approval follows FDA-approved labeling or accepted standards of medical practice.
    • For a higher dose, submit practice-guideline or peer-reviewed literature support.
    Denial Risk

    Unsupported Off-Label Regimen

    Off-label regimens require supporting evidence and must be FDA-approved or recommended by NCCN. Requests lacking the required evidence or using an unsupported regimen may be denied.

    • Submit practice-guideline or peer-reviewed literature supporting the relevant off-label use.
    • Identify the FDA-approved or NCCN-recommended regimen that supports the requested treatment.
    Testing may use tumor or plasma specimens
    RYBREVANT FASPRO Administration
    RouteSubcutaneous injection
    Administration siteAdministered in the abdomen
    Administration time and personnelAdministered by a health care professional over approximately five minutes; it cannot be self-administered
    EGFR tyrosine kinase inhibitor progression:
    RYBREVANT or RYBREVANT FASPRO is prescribed as subsequent therapy after progression on an EGFR tyrosine kinase inhibitor, disease is positive for an EGFR exon 19 deletion or exon 21 L858R substitution mutation, and treatment is combined with carboplatin and pemetrexed.
    Progression after EGFR tyrosine kinase inhibitor
  4. Lazcluze combination: RYBREVANT or RYBREVANT FASPRO is combined with Lazcluze for EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive disease and is prescribed as first-line therapy, continued after specified progression on the RYBREVANT/Lazcluze combination, or used after specified progression following Tagrisso-based therapy.EGFR exon 19 deletion or exon 21 L858R substitution mutation
  5. Brain metastases: The member has brain metastases, disease is positive for an EGFR exon 19 deletion or exon 21 L858R substitution mutation, and RYBREVANT or RYBREVANT FASPRO is combined with carboplatin and pemetrexed or Lazcluze.Brain metastases plus qualifying EGFR mutation
  6. Billing Rule

    Administer FASPRO in the office

    Administer subcutaneous RYBREVANT FASPRO in the abdomen over approximately five minutes by a health care professional in an office setting. It cannot be self-administered.

    • Confirm administration by a health care professional.
    • Do not substitute RYBREVANT FASPRO for or with IV RYBREVANT products.
    Billing Rule

    Administer FASPRO in hospital outpatient

    Administer subcutaneous RYBREVANT FASPRO in the abdomen over approximately five minutes by a health care professional in a hospital outpatient setting. It cannot be self-administered.

    • Confirm administration by a health care professional.
    • Do not substitute RYBREVANT FASPRO for or with IV RYBREVANT products.